AEVI-001
AEVI-001-ADHD-202
Phase 2 small_molecule completed
Quick answer
AEVI-001 for Attention Deficit Hyperactivity Disorder is a Phase 2 program (small_molecule) at Avalo Therapeutics with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Avalo Therapeutics
- Indication
- Attention Deficit Hyperactivity Disorder
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed